Country reports 2,622 new COVID-19 cases; 23 deaths in past 24 hrs

Source: RSS 6, Jul 2021

A total of 2,622 new cases of COVID-19 were reported in the country in the past 24 hours, according to the Ministry of Health and Population.

Pashupati Temple not to open in Shrawan for public

Source: RSS 6, Jul 2021

The Pashupati Area Development Trust has stated that the Pashupati temple will not open for the public in the upcoming holy month of Shrawan.

Achham declared fully literate district

Source: RSS 6, Jul 2021

With more than 95 per cent of literacy rate, Achham district was declared the fully literate district on Monday.

Hong Kong's Nepali expats provide oxygen concentrators

Source: RSS 6, Jul 2021

Hong Kong's Nepali expatriate community has led an initiative to help pandemic patients in Nepal's hilly districts.

Cathay Pacific Cargo rolls out Ultra Track worldwide

Source: RSS 5, Jul 2021

Multi-dimensional tracking system using Bluetooth technology offers near real-time monitoring for customers and proactive intervention when required

India reports 39,796 new COVID-19 cases

Source: RSS 5, Jul 2021

India's COVID-19 tally rose to 30,585,229 on Monday as 39,796 new cases were registered during the past 24 hours across the country.

Over a dozen villages flooded in Mahottari

Source: RSS 5, Jul 2021

Over a dozen villages in Mahottari district have been inundated as swollen local rivers have entered the settlements.

Communication access in Jumla’s Kankasundari

Source: RSS 5, Jul 2021

Kankasundari rural municipality, a remote place in Jumla district, has finally access to smooth communication services.

NAC resumes regular flight at Suketar airport from today

Source: RSS 5, Jul 2021

Nepal Airlines Corporation (NAC) has resumed its regular flight at Suketar airport of Taplejung district from today.

India's Bharat Biotech says COVID-19 vaccine Covaxin 77.8 pct effective in phase 3 trials

Source: Xinhuanet 5, Jul 2021

India's vaccine maker Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin has shown 77.8 percent efficacy in phase 3 clinical trials.

join our newsLetter

powered by : nepal traveller digital publication pvt. ltd

developed by : Web House Nepal